Last week I caught my second cold for the year and followed it up with a sinus infection for good measure. Unfortunately, it is only to be expected when the beautiful Australian summer finally gives way to autumn’s cool change, especially when you have heavily and deliberately suppressed your immune system for the better part of three years.
When “normal” people’s immune systems can not cope and average Joe starts coughing and spluttering, I am walking into a minefield of viral illnesses.
Last Monday was my first bi-weekly seminar for the year at university. The online noticeboard couldn’t stress enough how vital attendance was. Even though I knew how badly I needed to be there, it just wasn’t possible.
ImmuPharma PLC (LON:IMM) is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of innovative drugs to treat serious medical conditions, characterised by High unmet medical need,Low marketing costs and Relatively low development costs